Literature DB >> 20412746

[Immunopathogenesis of inflammatory bowel disease].

Julien Matricon1.   

Abstract

Inflammatory bowel diseases (IBD) are idiopathic, chronic and relapsing inflammatory conditions of the gastrointestinal tract. New insights into the pathogenesis of IBD have been provided by three lines of research: (1) studying susceptibility genes involved in the detection of bacterial components and in the regulation of the host immune response, (2) highlighting the disruption of tolerance towards the commensal microbiota and (3) unravelling the critical role of environmental factors such as sanitation and hygiene. This review presents current etiological hypothesis of IBD which argue that pathogenic intestinal bacteria and/or infectious agents initiate and perpetuate the inflammation of the gut in an individual with genetic vulnerability leading to impaired epithelial barrier function and abnormal mucosal immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412746     DOI: 10.1051/medsci/2010264405

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  11 in total

1.  Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.

Authors:  Abhijit A Date; Gilad Halpert; Taarika Babu; Jairo Ortiz; Pranjali Kanvinde; Peter Dimitrion; Janani Narayan; Hannah Zierden; Kalpana Betageri; Olivia Musmanno; Helen Wiegand; Xinglu Huang; Sanjeev Gumber; Justin Hanes; Laura M Ensign
Journal:  Biomaterials       Date:  2018-09-07       Impact factor: 12.479

Review 2.  The therapeutic potential of GPR43: a novel role in modulating metabolic health.

Authors:  Lauren M Cornall; Michael L Mathai; Deanne H Hryciw; Andrew J McAinch
Journal:  Cell Mol Life Sci       Date:  2013-07-14       Impact factor: 9.261

Review 3.  Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases.

Authors:  Merouane Bencherif; Patrick M Lippiello; Rudolf Lucas; Mario B Marrero
Journal:  Cell Mol Life Sci       Date:  2010-10-15       Impact factor: 9.261

4.  Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17.

Authors:  Yan Sun; Lian-Jie Lin; Yan Lin; Li-Xuan Sang; Min Jiang; Chang-Qing Zheng
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 5.  Dysbiotic events in gut microbiota: impact on human health.

Authors:  Serena Schippa; Maria Pia Conte
Journal:  Nutrients       Date:  2014-12-11       Impact factor: 5.717

6.  Lack of Adrenomedullin Aggravates Acute TNBS-Induced Colitis Symptoms in Mice, Especially in Females.

Authors:  Sonia Martínez-Herrero; Ignacio M Larrayoz; Judit Narro-Íñiguez; Susana Rubio-Mediavilla; Alfredo Martínez
Journal:  Front Physiol       Date:  2017-12-19       Impact factor: 4.566

7.  Design and Development of a Novel Peptide for Treating Intestinal Inflammation.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Jim N Petitte; Dayong Si; Zhongxuan Li; Junhao Cheng; Mengsi Du
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

8.  The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease.

Authors:  Hye Won Lee; Sook Hee Chung; Chang Mo Moon; Xiumei Che; Seung Won Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  Intestinal and peripheral fibrinogen-like protein 2 expression in inflammatory bowel disease.

Authors:  Xiuli Dong; Xiaohua Ye; Xiangrong Chen; Tanzhou Chen; Saili Xie; Qinfan Li; Xiaoxiao Lin; Zhiming Huang
Journal:  Dig Dis Sci       Date:  2013-11-28       Impact factor: 3.199

10.  C-Terminal Amination of a Cationic Anti-Inflammatory Peptide Improves Bioavailability and Inhibitory Activity Against LPS-Induced Inflammation.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Matthew Koci; Dayong Si; Baseer Ahmad; Henan Guo; Yanfei Hou
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.